There is no cure for glioblastoma. Standard treatment of surgery, radiation and temozolomide gives a median survival of about 15 months, and only about 7% of people live 5 years. That has barely changed in 20 years. Our view: progress will come from getting drugs and immune cells past the blood-brain barrier, and from combining treatments matched to each tumor.
This is Cure Checker's editorial assessment of published evidence, not medical advice. Treatment decisions belong with a neuro-oncology team, ideally at a center that treats many brain tumors.
Please read first. This is an AI-generated hypothesis, written by Cure Checker's AI from published research. It is speculation, not an established finding. It is not a recommendation, not a prediction that a cure exists, and not medical advice. No doctors or scientists have reviewed it, and it may be wrong. Never start, stop, change or delay any treatment because of it. Talk with your neuro-oncology team.
Opening the barrier can let more tumor DNA reach the blood. Could measuring it at each session show, before a scan can, that leftover cells are escaping a targeted immune treatment? If so, trials could test switching or adding targets while the tumor is small, using a test that does not yet exist.
What would prove it wrong: if this blood DNA does not change before regrowth shows on scans, or does not match targets in the regrown tumor.
Hypothesis written October 6, 2026. Cure Checker's AI will revisit it when major new evidence appears.
Newest first. Updated each morning as results, trial launches and papers are published.
Glioblastoma patients' platelets are more reactive, driven by a receptor called PAR4. In mice, blocking PAR4 extended survival in females but not males, and it depended on estrogen, working by freeing killer T cells to attack the tumor. Early lab work in mice; no PAR4 drug has been tested in glioblastoma patients.
In mouse models and human tumor samples, tumor cells reprogram nearby immune cells (microglia and macrophages) to release fat-like molecules that help the cancer invade surrounding brain. Blocking this loop reduced invasion in the lab. Early lab work, not tested in patients.
Company-reported, not peer-reviewed. Of 51 people enrolled, 44 were in the main analysis: median survival 19.6 months, and 19.9 months in 28 people with unmethylated MGMT. The comparison is to outside historical figures (12.7 to 15.5 months), not a control group. This is lower than the 29.3 months in the MGMT-unmethylated group reported in June from fewer people. Final data are expected in early 2027.
Generally well tolerated in 63 people with advanced cancers, 16 of them with recurrent glioblastoma. The report is about safety and how much drug reaches the brain tumor, and it plans a follow-up trial with spironolactone. Some authors work for the drug maker. No survival benefit shown.
Company-reported results, not yet peer-reviewed. In 233 evaluable people the vaccine did not reach its main goal: median survival was 22.8 months versus 20.3 months with placebo (p=0.076). In a pre-planned group aged 65 and under it was 24.2 versus 20.2 months (p=0.019). Serious side effects were similar in both groups. Not approved; a larger trial would be needed to confirm.
Not shown to be as good as standard radiation. Median survival was 13.0 versus 21.0 months, with more radiation damage (47.8% vs 16.2%). The trial stopped early with 135 of 474 planned patients.
Safe in a small pilot: no treatment-related deaths. Median survival 19.0 months, median time to progression 10.5 months. No comparison group.
Safe, but it did not reach its goal. Only 1 of 29 patients in the main stage responded (3.4%). Median survival was 10.2 months; median time before progression was 3.2 months. Single-arm trial.
The first FDA-approved FET-PET imaging drug for glioma. It helps tell recurrent tumor from treatment-related changes. It's for diagnosis, not treatment.
No delayed toxicity. Median survival 12.0 months, 28% alive beyond 18 months, one ongoing response at 33 months.
In 63 randomized people with recurrent, operable glioblastoma, giving two immune checkpoint drugs before surgery raised immune cells inside the tumor compared with placebo (the main goal). Median survival was 402 days with the two-drug approach versus 273 days with nivolumab alone, a secondary result from a small trial. No unexpected side effects were seen. It is not an approved treatment.
First-in-human trial opening at Duke for EGFRvIII-positive grade 4 glioma.
An IV mitochondrial therapy plus standard care. Median survival 19.3 months, and 29.3 months in the MGMT-unmethylated subgroup (39 evaluable patients).
Imvax plans a roughly 375-patient trial in MGMT-unmethylated newly diagnosed GBM after a Phase 2b subgroup signal.
Tests adding immunotherapy to Tumor Treating Fields and temozolomide in newly diagnosed GBM.
Median survival 31.3 months and progression-free survival 13.5 months, versus about 19 and 8 months in matched controls.
Standard care has changed little since 2005. The most encouraging new results come from opening the blood-brain barrier and from immune therapies placed directly into the brain. Most are still small, early trials.
Microbubbles plus focused ultrasound open the blood-brain barrier before each chemo dose. Median survival was 31.3 months, versus about 19 in 185 matched patients. It wasn't randomized, so a larger trial is needed.
Given into the brain's fluid. With longer follow-up there was no delayed toxicity, median survival was 12 months, 5 of 18 patients lived beyond 18 months, and one still had a response at 33 months.
A wearable device sends electric fields through the scalp to disrupt dividing cancer cells. Added to temozolomide, it extended survival in a Phase 3 trial. It's approved in the U.S., EU, Japan and China, but not routinely funded on the UK's NHS.
Made from the patient's own immune cells and tumor. The company reports longer survival compared with outside controls, a method that's been debated. The UK MHRA application has been under review since December 2023.
A modified herpes virus injected into the tumor. Japan gave it conditional, time-limited approval for malignant glioma. It was the world's first virus therapy approved for brain cancer.
Six radiation sessions instead of 30 didn't prove as good as standard care. Median survival was about 13 months, versus about 21. Standard-length radiation remains the norm.
| Treatment | For | What it does |
|---|---|---|
| Maximal safe surgery | Nearly everyone | Removes as much tumor as possible without harming key functions. |
| Radiation + temozolomide ("Stupp protocol," 2005) | Newly diagnosed | Six weeks of radiation with chemo, then six or more months of temozolomide. |
| Tumor Treating Fields | Newly diagnosed and recurrent | Worn on the head for most of the day, alongside chemo. |
| Lomustine, bevacizumab, re-operation | Recurrence | Second-line options. Bevacizumab mainly reduces swelling. |
| Steroids, seizure medicines | Symptoms | Reduce brain swelling and prevent seizures. |
No supplement or diet cures glioblastoma. A few are being studied alongside standard care, and some can interfere with chemo or surgery. We rate each by the strength of human evidence.
Small trials show it's feasible alongside treatment, but there's no proof it extends survival. Only try it with a dietitian, because weight loss is risky.
Lab studies are interesting, and small early trials have been run. It's not shown to control the tumor, but it may help appetite, nausea and sleep.
A small trial found less brain swelling after radiation. It isn't a tumor treatment. Ask before combining it with steroids.
Might blunt how radiation and chemo kill tumor cells. Skip large doses during treatment unless your team agrees.
Can change how seizure medicines and chemo are processed. Always check with your pharmacist.
Helps fatigue, strength and mood during and after treatment. Ask about seizure-safe activities.
Be careful: clinics abroad selling unproven "cures" for glioblastoma can be very costly and may delay treatment that works. Bring anything you're considering to your neuro-oncology team, and use the registries above to find real trials.
Centers recognized for expertise in this condition, and communities of people living with it.
An NCI-designated Comprehensive Cancer Center whose Tisch Brain Tumor Center cares for people with glioblastoma and offers clinical trials.
An NCI-designated Comprehensive Cancer Center whose Brain and Spine Center treats glioblastoma.
An NCI-designated Comprehensive Cancer Center with a Center for Neuro-Oncology that offers brain tumor clinical trials.
An NCI-designated Comprehensive Cancer Center that lists many glioblastoma trials, including the GBM AGILE platform trial.
Supported by German Cancer Aid as a Comprehensive Cancer Center, with a brain tumor program that includes the N2M2 glioblastoma trial.
These are centers recognized for expertise in this condition, not a ranking, and Cure Checker does not endorse or rate any facility. Outcomes depend on the individual. Ask your doctor which center fits your situation.
You don't have to face glioblastoma alone. These groups connect patients, families and caregivers with people who understand. Most are free.
Free virtual support conversations for patients, caregivers and grieving families, plus a peer mentor program.
Join a group ↗Support community, a CareLine, and glioblastoma education for every stage.
Get support ↗Free professional counseling and online support groups for people affected by glioblastoma.
Get help ↗Support line, online support groups and information for everyone affected by a brain tumour.
Get support ↗Long-running brain tumor support groups, a trial finder and treatment information (virtualtrials.org).
Visit ↗A large, general cancer support community on Reddit.
Open on Reddit ↗Many patient and caregiver groups. This link searches Facebook (a login is required).
Search Facebook ↗Before you join: support groups share experiences, not medical advice. Check anything about treatment with your doctor. Think about your privacy, because Reddit and many forums are public, and never share passwords or financial details. Cure Checker isn't affiliated with these groups.
Surgery, radiation and temozolomide are standard everywhere. The differences are in the extras. Japan approved a cancer-killing virus. The UK is reviewing a personalized vaccine. Tumor Treating Fields are routine in some countries and hard to get in others.
| Treatment | U.S. | EU | UK | Canada | Japan | S. Korea | China | Australia | Switz. |
|---|---|---|---|---|---|---|---|---|---|
| TemozolomideStandard chemo | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Tumor Treating FieldsOptune device | Yes | Yes | Not on NHS | 2022 | Yes | — | Yes | — | Yes |
| DelytactOncolytic virus | — | — | — | — | 2021, conditional | — | — | — | — |
| DCVax-LDendritic-cell vaccine | — | — | Under review | — | — | — | — | — | — |
| Pixclara (FET-PET)Imaging, not treatment | 2026 | — | — | — | — | — | — | — | — |
The world's first approved virus therapy for brain cancer. Approval was conditional and time-limited, based on a single-arm Phase 2 that met its one-year survival goal.
Still under review in 2026 and not refused. The UK's NICE won't assess it until a license is granted.
Available through public health systems in several countries, but not routinely on the UK's NHS. Access depends heavily on where you live.
Glioblastoma is the most common and most aggressive primary brain cancer in adults. It grows from glial cells, the cells that support neurons. For almost everyone it isn't inherited and has no known cause. Random DNA changes build up until a cell grows out of control.
Live numbers and the newest entries from the world's main trial registries and medical databases. Most of this loads fresh each time you open the page.
Loading live data from ClinicalTrials.gov…
Loading…
Loading…
Loading…
| Medicine | Brand | FDA application | Original approval |
|---|
From Drugs@FDA via FDA's openFDA service. Some older brands are missing from FDA's open data, and newly approved drugs can take a few weeks to appear. An approval may be for a different disease than this one.
The WHO's ICTRP gathers trials from registries worldwide, including China, Japan, India, Iran, Australia and Brazil. Cochrane CENTRAL and OpenMD don't allow automated access, so they're linked here for you to search directly.
These brain-tumor organizations exist to help families affected by glioblastoma pay for care and costs. Several were closed to new applications when checked. Funds are limited and rules vary, so contact each one directly.
Grants of $100 to $750, paid straight to the vendor, for travel and lodging to reach treatment or trials, or bills such as rent, utilities and medical costs. Applications were open when checked; awards depend on funds.
See the program ↗Pays up to three bills per application, up to $1,500 in total, such as rent or mortgage, utilities, car payments, insurance or medical bills. Decisions take 3 to 5 weeks and depend on available funds.
See the program ↗Grants for practical costs insurance doesn't fully cover, such as travel and lodging for care or second opinions, caregiving and home accommodations. The page gives no amounts or limits.
Apply for a grant ↗Pays bills for households facing hardship, up to $3,000 per approved application and one per family every 365 days. The board decides which expenses qualify.
See the program ↗One-time grants of $250 to $1,000 toward up to two current bills, such as rent, utilities, medical bills or insurance, funded by the Glenn Garcelon Fund. Applications are taken the 1st to 15th of each month; the page said it was temporarily closed.
Check status ↗Flexible grants of up to $5,000 a year toward in-home care or unpaid leave, travel for care, uncovered medicines and bills. Not taking new applications when checked; it expects to reopen in December 2026.
See the program ↗A brain tumor drug copay program for certain glioblastoma treatments, up to $5,000 a year. When checked it said it had run out of funding and was not accepting new or renewal applications.
Check status ↗Helps pay copays, coinsurance, deductibles and insurance premiums. The fund was listed as closed on October 6, 2026; the page offers alerts for when it reopens.
Check fund status ↗Helps pay prescription copays for glioblastoma treatment, or Medicare Part B premiums. The fund was listed as closed to new patients on October 6, 2026.
Check fund status ↗Before you apply: Cure Checker does not run, verify or endorse these organizations, and being listed is not a promise of help. Funds are limited and rules change, so confirm eligibility and details with each organization. Be careful of anyone who asks for payment up front or for your bank login to 'release' a grant.
Everything this report is based on, grouped by section. Checked October 2, 2026.
The risk factors, WHO 2021 definition, the 2005 Stupp protocol, the 2015 U.S. Tumor Treating Fields approval, and the diet, cannabis, boswellia, antioxidant and herb notes reflect the established published record. They don't yet have individual citations here. Expert care centers: NCI designation covers each cancer center as a whole, not glioblastoma results; the glioblastoma programs come from each center's own pages. Cancer Center designation is not a measure of outcomes. Financial help: checked October 6, 2026. Kim's Hope, the Musella copay program and both copay charities were closed to new applications that day, and the American Brain Tumor Association page carried two conflicting reopening notices. Grapes for Glioblastoma is a small new program that publishes no amounts or eligibility rules. Mission4Maureen's site could only be read through a fetch tool. The Darren Daulton Foundation's rules come from its application form.